Physician profile
Laura Wagner
NPI 1669445060
$16,044.42
in general payments reported to CMS, 2019-2025
28 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $2,314 · 2021: $2,318 · 2022: $2,172 · 2023: $1,782 · 2024: $2,374 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,813 · Education: $32.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,813.31 |
| Education | $32.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,281.45 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,662.38 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $1,348.86 | 2019-2025 | |
| Lilly USA, LLC | $1,154.66 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Ucb, INC. | $1,087.79 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,062.49 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $899.89 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $782.23 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $552.51 | 2023-2024 | Vtama |
| Leo Pharma INC. | $512.63 | 2019-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $454.44 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $384.53 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $373.68 | 2019-2024 | Cabtreo |
| Almirall LLC | $350.80 | 2019-2025 | Klisyri |
| Incyte Corporation | $305.70 | 2021-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $285.60 | 2019-2025 | |
| Genzyme Corporation | $284.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $280.90 | 2020-2022 | |
| Celgene Corporation | $263.59 | 2019 | |
| Organon LLC | $159.27 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $124.10 | 2019 | |
| Dermira, INC. | $112.49 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $97.50 | 2023-2025 | Zoryve |
| Botanix Sb INC | $79.66 | 2025 | Sofdra |
| Epi Health, LLC | $68.62 | 2021-2022 | |
| Mission Pharmacal Company | $42.90 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $15.86 | 2020 | |
| Sandoz INC. | $15.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.